Physician profile
Neil Manek
NPI 1891950234
$7,697.34
in general payments reported to CMS, 2019-2025
25 companies · $3,349 in 2025
The $3,349 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $257 · 2021: $168 · 2022: $93.46 · 2023: $387 · 2024: $2,441 · 2025: $3,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,623 · Food and Beverage: $1,538 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,623.00 |
| Food and Beverage | $1,537.59 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $4,769.95 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $802.44 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $452.85 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $240.56 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $167.02 | 2019-2020 | |
| Medtronic, INC. | $146.92 | 2023-2025 | Symplicity G3, Endurant Iis |
| Akebia Therapeutics INC | $144.17 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.51 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $117.66 | 2023-2024 | Jynarque |
| Glaxosmithkline, LLC. | $76.72 | 2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $72.93 | 2025 | |
| Baxter Healthcare | $72.15 | 2019 | |
| Mozarc Medical US LLC | $71.41 | 2023-2025 | Chameleon, Palindrome |
| Amgen INC. | $67.16 | 2020-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $55.57 | 2022-2023 | Lupkynis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46.70 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $42.63 | 2022 | |
| Travere Therapeutics, INC. | $38.38 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $33.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.26 | 2020 | |
| Apellis Pharmaceuticals, INC. | $29.59 | 2025 | Empaveli |
| Novo Nordisk INC | $28.73 | 2025 | Ozempic |
| Cordis US Corp. | $21.95 | 2024 | Saber |
| W. L. Gore & Associates, INC. | $21.12 | 2025 | Gore Viabahn Endoprosthesis |
| Scpharmaceuticals INC. | $16.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Manek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.